Innoviant by Prescription Solutions, headquartered in the United States, is a prominent player in the pharmacy benefit management (PBM) industry. Founded in 2001, the company has established itself as a leader in optimising prescription drug benefits for employers and health plans across the nation. With a focus on innovative solutions, Innoviant offers a range of services including formulary management, cost containment strategies, and clinical support programmes. Their unique approach combines advanced analytics with personalised service, ensuring clients receive tailored solutions that enhance patient outcomes while controlling costs. Recognised for its commitment to transparency and efficiency, Innoviant has achieved significant milestones in improving medication adherence and reducing overall healthcare expenses. As a trusted partner in the PBM landscape, Innoviant continues to set benchmarks for excellence in prescription management.
How does Innoviant by Prescription Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Innoviant by Prescription Solutions's score of 60 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Innoviant by Prescription Solutions, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. However, the organisation's climate commitments and reduction initiatives are influenced by its parent company, UnitedHealth Group Incorporated, from which it inherits emissions data and sustainability targets. As part of its corporate family, Innoviant aligns with the climate strategies set forth by UnitedHealth Group, which has established science-based targets for emissions reductions. These targets are cascaded down through the corporate structure, reflecting a commitment to addressing climate change and reducing carbon footprints across its operations. While specific reduction targets or achievements for Innoviant are not detailed, the overarching initiatives from UnitedHealth Group indicate a proactive approach to sustainability. The company is engaged in various climate-related initiatives, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which guide its emissions reduction strategies. In summary, while Innoviant by Prescription Solutions does not provide specific emissions data or reduction targets, it is committed to climate action through its association with UnitedHealth Group, which sets the framework for its environmental sustainability efforts.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 15,838,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 161,303,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 3 | 146,373,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 
Innoviant by Prescription Solutions's Scope 3 emissions, which decreased by 3% last year and increased significantly since 2016, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Investments" being the largest emissions source at 51% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Innoviant by Prescription Solutions has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.